Anders Vadsholt

Chief Financial Officer

Anders Vadsholt (born 1969) was appointed in 2025 and holds the overall responsibility for Camurus’ financial operations and oversees the development of the company’s financial organization to support strategic and financial goals in a compliant and efficient manner.

He has more than 25 years of experience in corporate finance, venture capital, and the biotechnology industry. For more than 15 years, he has held executive leadership roles in late-stage and publicly traded biotech companies. Recently, he served as both CEO and CFO of Orphazyme A/S, where he led the company through its dual listings on the Nasdaq Copenhagen and Nasdaq New York exchanges. His previous positions include CFO roles at MinervaX ApS and Topotarget A/S. He began his career in investment banking at Carnegie and in venture capital at BankInvest Biomedical Venture.

Anders holds an MSc in Corporate Law and Economics from Copenhagen Business School and an MBA from the University of Melbourne.

Other current appointments:  Board member of Amplify Therapeutics ApS.

Holdings in the company: 2,300 Performance Share Plan units.